Business
GM Statement
GM Statement.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 1981A Futura Medical PLC 17 January 2020 \n\n \n17 January 2020\nResult of General Meeting, Issue of Equity, Admission and Total Voting Rights\nFutura Medical plc (AIM: FUM) (the \"Company\"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology and focused on sexual health and pain, announces that, at its General Meeting held earlier today, all resolutions were duly passed by the shareholders.\nApplication has been made to the London Stock Exchange for 40,625,000 Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will be effective and trading will commence at 8.00 a.m. on 20 January 2020.\nFollowing Admission, the Company will have 245,285,267 Ordinary Shares in issue. As the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 245,285,267 and this figure may therefore be used by Shareholders. \nTerms in this announcement have the meaning given to them in the Circular issued in connection with the Fundraising and the announcement released on 20 December 2019 with the RNS Number 7183X. \nFor further information please contact:\nFutura Medical plc \nJames Barder, Chief Executive\nAngela Hildreth, Finance Director and COO\nEmail: [email protected]\nTel: +44 (0) 1483 685 670\nwww.Futuramedical.com\n \nNominated Adviser and Sole Broker:\nLiberum\nBidhi Bhoma/ Euan Brown/ Kane Collings\nTel: +44 (0) 20 3100 2000\n \nFor media enquiries please contact:\nOptimum Strategic Communications\nMary Clark/ Eva Haas/ Hollie Vile\nEmail: [email protected]\nTel: +44 (0) 203 950 9144\n \n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END GMSBRMTTMTBBBMM\n ","length":3419,"tagName":"div"}]